视网膜生物製剂市场规模、份额和成长分析（按药物类别、适应症、通路和地区划分）—2026-2033年产业预测

预计到 2024 年，全球视网膜生物製剂市场规模将达到 246.4 亿美元，到 2025 年将达到 265.1 亿美元，到 2033 年将达到 476.4 亿美元，预测期（2026-2033 年）的复合年增长率为 7.6%。

视网膜生物製剂市场正经历显着成长，主要受视网膜疾病（尤其是老龄化黄斑部病变、糖尿病视网膜病变和视网膜静脉阻塞）发病率上升的推动，而人口老化是造成此现象的主要原因。生物技术和基因工程的进步为基因疗法和细胞疗法等有效治疗方法开闢了新的可能性，从而刺激了相关研究和开发。大众对这些疾病的认识不断提高，加上诸如预防失明基金会等机构的教育宣传，提高了人们对早期诊断和治疗方案的了解。在新兴市场，特别是中国、巴西和印度等国家，医疗基础设施的改善和VEGF-A拮抗剂疗法的日益普及正在推动市场进一步成长。整体而言，视网膜生物製剂市场前景广阔，成熟市场和发展中市场均对此表示支持。

全球视网膜生物製剂市场驱动因素

美国糖尿病视网膜病变发生率的上升正对全球视网膜生物製剂市场产生重大影响。许多患者被诊断出患有此病，面临更高的视力丧失风险。随着糖尿病视网膜病变盛行率的持续增长，对有效治疗方法的需求也日益增加。预计这一趋势将推动对视网膜生物製剂的需求，从而显着扩大市场规模。人们对视觉健康的日益关注以及对创新解决方案的需求，将在未来几年进一步促进市场成长。

限制全球视网膜生物製剂市场的因素

全球视网膜生物製剂市场面临严峻挑战，其中最主要的原因是这些药物价格高昂，发展中国家的患者难以负担治疗费用，这限制了他们获得治疗的机会。此外，生物製药的研发和商业化过程本身就十分复杂，而严格的监管要求更使其雪上加霜，可能阻碍市场扩张。这些障碍不仅限制了病患的用药，也延缓了创新治疗方法的推出，最终影响到经济和基础设施资源匮乏地区的病患治疗效果。因此，这些因素共同限制了视网膜生物製剂市场的成长。

全球视网膜生物製剂市场趋势

全球视网膜生物製剂市场正经历重大变革，其主要驱动力是基因治疗方法的进步，包括针对遗传性视网膜营养不良的基因疗法。这些研发成果正在革新治疗格局，并提升视网膜生物製剂的疗效。这促使创新治疗方案的涌现，以满足视网膜疾病患者尚未满足的需求。加之生物製药创新领域投资的不断增加以及对视网膜病理学认识的不断深入，这一市场趋势预示着视网膜疾病患者拥有光明的未来，有望获得更佳的治疗效果和更高的生活品质。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管环境
• 案例研究
• 技术进步
• 贸易分析
• 客户和购买标准分析

全球视网膜生物製剂市场规模（按药物类别和复合年增长率划分）（2026-2033 年）

• VEGF-A拮抗剂
• TNF-α抑制剂

全球视网膜生物製剂市场规模（按适应症和复合年增长率划分）（2026-2033 年）

• 老龄化黄斑部病变
• 糖尿病黄斑部水肿
• 糖尿病视网膜病变
• 葡萄膜炎
• 其他的

全球视网膜生物製剂市场规模（依通路划分）及复合年增长率（2026-2033 年）

• 向医疗机构销售
• 零售药房
• 邮购药房
• 零售

全球视网膜生物製剂市场规模（按地区划分）及复合年增长率（2026-2033 年）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• F. Hoffmann-La Roche Ltd（Switzerland）
• Regeneron Pharmaceuticals Inc.（USA）
• AbbVie Inc.（USA）
• Novartis AG（Switzerland）
• Bayer AG（Germany）
• Amgen Inc.（USA）
• Johnson & Johnson（USA）
• Biogen Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Bristol-Myers Squibb Company（USA）
• Sanofi Genzyme（France）
• Santen Pharmaceutical Co., Ltd.（Japan）
• Bausch & Lomb Incorporated（USA）
• Adverum Biotechnologies, Inc.（USA）
• MeiraGTx Holdings plc（UK）
• Oxurion NV（Belgium）
• Kodiak Sciences Inc.（USA）
• Clearside Biomedical, Inc.（USA）
• Neurotech Pharmaceuticals, Inc.（USA）
• Opthea Limited（Australia）

结论与建议

Global Retinal Biologics Market size was valued at USD 24.64 Billion in 2024 and is poised to grow from USD 26.51 Billion in 2025 to USD 47.64 Billion by 2033, growing at a CAGR of 7.6% during the forecast period (2026-2033).

The retinal biologics market is witnessing significant growth driven by an increase in retinal diseases, particularly age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion, primarily due to an aging population. Advancements in biotechnology and genetic engineering are unlocking new potential for effective treatments, such as gene and cell-based therapies, encouraging a resurgence in research and development. Growing public awareness of these conditions, alongside advocacy from organizations like the Foundation Fighting Blindness, is enhancing recognition for early diagnosis and treatment options. Emerging markets, particularly in countries like China, Brazil, and India, are further boosting growth through improved healthcare infrastructure and increased adoption of VEGF-A antagonist therapies. Overall, the retinal biologics market presents a promising outlook fueled by both established and developing regions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Retinal Biologics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Retinal Biologics Market Segments Analysis

Global Retinal Biologics Market is segmented by Drug Class, Indication, Distribution Channel and region. Based on Drug Class, the market is segmented into VEGF-A Antagonists and TNF-a Inhibitors. Based on Indication, the market is segmented into Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Uveitis and Others. Based on Distribution Channel, the market is segmented into Institutional Sales, Retail Pharmacies, Mail Order Pharmacies and Retail Sales. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Retinal Biologics Market

The rising incidence of diabetic retinopathy in the United States is significantly influencing the Global Retinal Biologics market. A substantial number of individuals are diagnosed with this condition, with many at an increased risk of vision impairment. As the prevalence of diabetic retinopathy continues to grow, so does the urgency for effective treatment options. This trend is expected to propel the demand for retinal biologics, leading to substantial market expansion. The increasing awareness of visual health and the need for innovative solutions to address this widespread issue will further contribute to the market's growth trajectory in the forthcoming years.

Restraints in the Global Retinal Biologics Market

The global retinal biologics market faces significant challenges due to the high costs associated with these drugs, limiting access for individuals in developing countries who often struggle to afford such treatments. Additionally, the complex process of developing and commercializing these biologics is compounded by stringent regulatory requirements, which can further impede market expansion. These barriers not only restrict accessibility but also slow down the introduction of innovative therapies, ultimately affecting patient outcomes in regions where financial and infrastructural resources are limited. As a result, these factors collectively pose notable restraints on the growth of the retinal biologics market.

Market Trends of the Global Retinal Biologics Market

The Global Retinal Biologics market is witnessing a significant shift driven by advancements in genetic treatment approaches, particularly in gene therapy for inherited retinal dystrophies. These progressive research developments are revolutionizing the therapeutic landscape, enhancing the efficacy of retinal biologic drugs. As a result, a surge in innovative treatment options is emerging, catering to the unmet needs of patients with retinal disorders. Coupled with increasing investments in biopharmaceutical innovation and a growing understanding of retinal pathology, this market trend is indicative of a brighter future for those affected by retinal diseases, promising improved outcomes and quality of life.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement
• Trade Analysis
• Customer & Buying Criteria Analysis

Global Retinal Biologics Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• VEGF-A Antagonists
• TNF-a Inhibitors

Global Retinal Biologics Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Macular Degeneration
• Diabetic Macular Edema
• Diabetic Retinopathy
• Uveitis
• Others

Global Retinal Biologics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Institutional Sales
• Retail Pharmacies
• Mail Order Pharmacies
• Retail Sales

Global Retinal Biologics Market Size & CAGR (2026-2033)

• North America (Drug Class, Indication, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Indication, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Indication, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Indication, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Indication, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi Genzyme (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch & Lomb Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adverum Biotechnologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MeiraGTx Holdings plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxurion NV (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kodiak Sciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clearside Biomedical, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurotech Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Opthea Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations